Mark Lloyd is Alvotech’ s Chief Operations Officer (COO). He leads strategic initiatives that increase operational efficiency to realize our vision.
Mark has over 25 years of experience in global drug development across various disciplines. Prior to joining Alvotech, he served as VP of Global Project Management with Sandoz Biopharmaceuticals, a Novartis business unit. He has previously held leadership roles in Operational Excellence, Clinical Development and Operations with Novartis, Sanofi and Schering-Plough (now Merck). Through his various leadership roles, Mark has been a key contributor to the approval of nine innovative and biosimilar pharmaceutical products.
Mark holds a dual Bachelor of Science in Neuroscience and Psychology from the University of Pittsburgh (Pennsylvania, USA) and an Executive MBA from Rutgers Business School, (New Jersey, USA).